Introduction
============

The mortality rate from colorectal cancer is the third highest in men (being behind that of lung and prostate cancer) and second in women (being behind breast cancer) in the United States ([@b1-ol-0-0-6817]). Even when patients undergo curative surgery for advanced cancer, recurrence can still occur. Markers that relate closely to cancer progression and metastasis would enable early diagnosis and intervention. Thus, the identification of novel markers that predict cancer progression is important for planning clinical strategies. In addition, the identification of such markers could lead to the development of novel therapeutic agents. In colorectal cancer, various molecular-targeted drugs have been developed and clinically applied in previous years ([@b2-ol-0-0-6817]--[@b8-ol-0-0-6817]). In addition, the assessment of specific genes including cancer progression gene sets via development of chip technology has led to tailor-made therapy.

The present study focused on the Golgi-associated PDZ- and coiled-coil motif-containing (GOPC) since it has been reported that the knockdown of GOPC in cells increases activation of the mitogen-activated protein kinase (MAPK)-extracellular signal-regulated kinase (Erk) 1/2 pathway. The MAPK-Erk1/2 pathway is a chief cellular signal transduction pathway that regulates cell differentiation, proliferation, survival and migration in colorectal cancer ([@b9-ol-0-0-6817]--[@b13-ol-0-0-6817]). The present study aimed to elucidate the correlation between GOPC expression and clinicopathological factors and prognosis in colorectal cancer.

Materials and methods
=====================

### Patients and samples

GOPC expression was assessed for each of nine clinical samples of colorectal cancer and normal mucosa using reverse transcription-quantitative PCR (RT-qPCR). An additional 153 clinical colorectal cancer samples were used to assess the correlation of GOPC expression and clinicopathological factors or prognosis. For immunohistochemical analysis, 10 normal colorectal mucosa and 10 colorectal cancer tissue specimens were used. All samples were obtained by surgery between March 2003 and June 2006 at Osaka University, Minoh City Hospital, Kansai Rosai Hospital, Kinki Central Hospital of the Mutual Aid Association of Public School Teachers, National Hospital Organization Osaka National Hospital, NTT (Nippon Telegraph And Telephone) West Osaka Hospital, Osaka Medical Center for Cancer and Cardiovascular Diseases, Saiseikai Suita Hospital, Sakai City Medical Center and Toyonaka Municipal Hospital (all in Osaka, Japan). Every patient provided informed consent and the present study was approved by the Research Ethics Board of each institution.

### Assessment of tumor stage

Tumor stages were defined according to the tumor node metastasis (TNM) staging system ([@b14-ol-0-0-6817]).

### Assessment of clinicopathological and prognostic factors

The present study assessed the correlation between GOPC expression and clinical characteristics, venous invasion, lymph invasion, tumor invasion, lymph node metastasis, TNM stage, overall survival (OS) and recurrence-free survival (RFS). The 153 colorectal cancer samples included 32 TNM stage 0/I cases, 45 stage II cases, 58 stage III cases and 18 stage IV cases according to the UICC classification for colorectal cancer.

### Processing mRNA and RT-qPCR

Total RNA was extracted from frozen tumor tissue using miRNeasy Mini kit (Qiagen AB, Sollentuna, Sweden). No DNase treatment was performed. Total RNA was then reverse transcribed to cDNA using the High Capacity RNA-to-cDNA™ kit (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA), according to the manufacturer\'s protocol. cDNA was the amplified by RT-qPCR using the Light Cycler^®^ 2.0 DX400 (Roche Diagnostics, Basel, Switzerland). The PCR reaction mixture consisted of 0.5 µl of cDNA, 5.0 µl of THUNDERBIRD™ SYBR^®^ qPCR Mix (Toyobo Co., Ltd., Osaka, Japan), 4.0 µl of water and 0.5 µl of each primer. The GOPC primers were: Forward, 5′-GTGGATGTGGATCTGCTCCT-3′ and reverse, 5′-CCTCCAGCTTGTGGTTGATT-3′. Primers for GAPDH, the internal control, were: Forward, 5′-CAACTACATGGTTTACATGTTC-3′ and reverse, 5′-GCCAGTGGACTCCACGAC-3′. The normalization was performed by standard curve method ([@b15-ol-0-0-6817]). The amplification protocol consisted of 55 cycles of: Denaturation at 95°C for 5 sec, annealing at 60°C for 5 sec and extension at 72°C for 30 sec. The RT-qPCR experiment was performed 7 times.

### Immunohistochemical staining

The expression of the GOPC protein was assessed by immunohistochemical staining of formalin-fixed and paraffin-embedded normal colorectal mucosa and colorectal cancer tissue sections. The surgical tissue samples were placed overnight at room temperature in 10% formalin before paraffin embedding. Briefly, 3.5 µm thick sections were incubated overnight at 4°C using the rabbit polyclonal anti-GOPC antibody (dilution, 1:1,000; \#ab37036; Abcam, Cambridge, UK) subsequent to immersion and blockade of endogenous peroxidase activity. The blocking was for 20 min at room temperature using VECTASTAIN Elite ABC horseradish peroxidase kit (Rabbit IgG; \#PK-6101; Vector Laboratories, Burlingame, CA, USA). Hematoxylin was used for nuclear staining for 1 min. Dehydration was performed using 60, 70, 80, 90 and 95% ethanol for 1 min each, 100% ethanol for 2 min twice and xylene for 5 min, 3 times. The specimens were visualized on the light field using a confocal microscope BZ-X710 (Keyence Corporation, Osaka, Japan) and BZ-X analyzer (v. 1.3.0.3; Keyence Corporation).

### Statistical analyses

Statistical analyses were performed using Fisher\'s exact tests to compare the differences between the two groups. The cumulative probabilities of OS or RFS were compared between these two groups by the Kaplan-Meier method with the log-rank test to calculate significant differences. Cases of non-curative resection were excluded from the RFS analyses. Univariate and multivariate analyses for OS and RFS were performed to evaluate independent prognostic factors using a Cox proportional hazards model. All statistical analyses were performed with JMP Pro software (version 11; JMP, Buckinghamshire, UK). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Correlation between GOPC mRNA expression and clinicopathological factors

Firstly, RT-qPCR was used to assess the expression of GOPC in normal colorectal mucosa and colorectal cancer tissue in nine clinical samples. The Wilcoxon rank-sum test was used to assess the statistical significance. GOPC expression in normal colorectal mucosa specimens was significantly increased compared with colorectal cancer specimens (P=0.002; [Fig. 1A](#f1-ol-0-0-6817){ref-type="fig"}). The GOPC expression in the additional 153 colorectal cancer specimens was then assessed. Data obtained from RT-qPCR was investigated to see if it fit Gaussian distribution with the Shapiro-Wilk test, and it did not. Thus, the median value was used to classify the higher (GOPC high) and lower (GOPC low) expression groups and clinicopathological characteristics were assessed based on the level of GOPC expression. Based on the median score to separate the GOPC high and low groups ([Fig. 1B](#f1-ol-0-0-6817){ref-type="fig"}), there were 77 GOPC high cases, and 76 GOPC low cases. The baseline characteristics are presented in [Table I](#tI-ol-0-0-6817){ref-type="table"}. The GOPC high group included 48 men and 29 women whereas the GOPC low group included 47 men and 29 women. The groups did not differ in the site of primary disease or size of the primary tumor, and CEA and CA19-9 levels also did not differ. In the analysis of clinicopathological factors, the proportion of positive venous invasion was significantly increased in the GOPC low group compared with the GOPC high group (P=0.001). Histological type, lymphatic invasion, depth of tumor invasion, lymphatic nodule metastasis, and TNM stages were not observed to differ between the two groups ([Table II](#tII-ol-0-0-6817){ref-type="table"}).

### Correlation between GOPC mRNA expression and clinical outcome

The correlation between GOPC expression and clinical outcome was assessed by comparison of the GOPC high and low groups. OS and RFS were assessed by the Kaplan-Meier method using the log-rank test. The Kaplan-Meier curves demonstrated that there was a significantly poorer OS in the GOPC low group compared with the GOPC high group (P=0.015; [Fig. 2A](#f2-ol-0-0-6817){ref-type="fig"}). Univariate and multivariate analyses identified lymphatic invasion to be an independent prognostic factor for OS \[hazard ratio (HR)=7.628; 95% confidence interval (CI), 1.441--141.2; P=0.012; [Table III](#tIII-ol-0-0-6817){ref-type="table"}\].

The correlation of GOPC expression and RFS was assessed in 131 patients (22 of the 153 patients had undergone non-curative surgery and were excluded from RFS analysis). Adjuvant chemotherapy was used in 27 GOPC high and 24 GOPC low cases. The 4 regimens of adjuvant chemotherapy were: Uracil-tegafur with leucovorin; Uracil-tegafur with doxifluridine; Uracil-tegafur with irinotecan; 5-fluorouracil with l-leucovorin. Relapse was observed in 25 patients: 8 in the GOPC high group and 17 in the GOPC low group. The proportion of recurrence was significantly higher in the GOPC low group (P=0.049; [Table IV](#tIV-ol-0-0-6817){ref-type="table"}). The Kaplan-Meier curves indicated that RFS was significantly reduced in the GOPC low group compared with the GOPC high group (P=0.020; [Fig. 2B](#f2-ol-0-0-6817){ref-type="fig"}). Univariate and multivariate analyses identified lymph node metastasis (HR=2.861; 95% CI, 1.138--7.880; P=0.024) and lower GOPC expression (HR=2.800; 95% CI, 1.121--7.648; P=0.027) to be independent prognostic factors for RFS ([Table V](#tV-ol-0-0-6817){ref-type="table"}).

In analyses according to each stage, OS in the GOPC low group was poorer compared with in the GOPC high group at stage III (P=0.044) and stage IV (P=0.054; [Fig. 3](#f3-ol-0-0-6817){ref-type="fig"}).

### Expression of GOPC protein in normal colorectal mucosa and colorectal cancer tissue

Immunohistochemical analysis was performed to assess the protein expression of GOPC in 10 sections each of normal colorectal mucosa and colorectal cancer tissue. Representative staining of GOPC in the normal colorectal mucosa and colorectal cancer tissue was observed ([Fig. 4](#f4-ol-0-0-6817){ref-type="fig"}). GOPC protein expression in normal mucosa was increased compared with in cancer tissue and expression localized in the cytoplasm or cell surface membrane ([Fig. 4A and B](#f4-ol-0-0-6817){ref-type="fig"}). As for the GOPC expression in cancer tissue, a high expression was observed at the surface of cancerous tissue, whilst low expression was observed at the invasive front ([Fig. 4C and D](#f4-ol-0-0-6817){ref-type="fig"}).

Discussion
==========

GOPC, also known as PDZ domain protein interacting specifically with TC10 or Fused in Glioblastoma (FIG), and cystic fibrosis transmembrane conductance regulator-associated ligand, controls the trafficking of numerous integral membrane proteins from the trans-Golgi network to the cell surface ([@b16-ol-0-0-6817]--[@b19-ol-0-0-6817]). Its domain structure consists of an N-terminal region with two coiled-coil domains and a C-terminal PDZ domain ([@b16-ol-0-0-6817]). The PDZ domain mediates interactions with frizzled, a Wnt receptor ([@b16-ol-0-0-6817]), and TC10, a member of the Rho-family GTPases ([@b17-ol-0-0-6817]). In addition, GOPC regulates various proteins including the soluble N-ethylmaleimide sensitive fusion protein attachment protein receptor (Q-SNARE) protein syntaxin-6 involved in endocytosis ([@b19-ol-0-0-6817]), cluster of differentiation-46 in autophagy ([@b20-ol-0-0-6817]) and claudin-1 and claudin-2 in tight junctions ([@b21-ol-0-0-6817]). In glioblastoma, GOPC (or FIG) is reported to fuse with the c-ros-oncogene 1 (ROS), a type of receptor tyrosine kinase, yielding the so-called FIG-ROS ([@b22-ol-0-0-6817]). Certain studies have indicated that FIG-ROS performs oncogenic roles in several processes, including cellular proliferation, colony formation, cell cycle progression, migration and invasion in intrahepatic cholangiocarcinoma ([@b23-ol-0-0-6817],[@b24-ol-0-0-6817]). To the best of our knowledge, no study has previously been published regarding GOPC and FIG-ROS in colorectal cancer.

GOPC mRNA expression was evaluated in 153 colorectal cancer specimens by RT-qPCR and the correlation between GOPC expression and prognosis was analyzed. In the analyses of the clinicopathological factors, the proportion of venous invasion was significantly increased in the GOPC low group compared with in the GOPC high group, as was the proportion of cancer recurrence. The number of stage IV cases (11 in GOPC low, 7 in GOPC high) and the number of hematogenous metastasis cases (8 in GOPC low, 4 in GOPC high) were greater in the GOPC low group. Multivariate analysis for RFS identified lower expression of GOPC to be an independent prognostic factor.

To compare the expression of GOPC mRNA and protein between normal colorectal mucosa and cancerous tissue, RT-qPCR and immunohistochemical analysis were performed. The expression of GOPC mRNA and protein in the normal colorectal mucosa was increased compared with cancer tissue, suggesting that the colorectal mucosa loses GOPC expression during carcinogenesis events. Immunohistochemical analysis demonstrated that the expression of GOPC protein in cancer tissue, particularly in front invasion of cancer, was lower compared with normal mucosa. Combined with the RT-qPCR and immunohistochemical findings of GOPC expression, this result suggests that loss of GOPC performs an important role in cancer malignancy.

GOPC also controls postendocytic sorting of several receptors toward lysosomal degradation ([@b25-ol-0-0-6817]--[@b28-ol-0-0-6817]) and reduces the amount of cell surface receptors ([@b29-ol-0-0-6817],[@b30-ol-0-0-6817]). GOPC binds to G protein-coupled receptors with a PDZ ligand motif, including metabotropic glutamate receptors ([@b31-ol-0-0-6817],[@b32-ol-0-0-6817]), the somatostatin receptor subtype 5 ([@b30-ol-0-0-6817],[@b33-ol-0-0-6817]). It was recently reported that GOPC knockdown in the HEK293 cell line reduces internalized β1-AR and increases cell surface β1-AR ([@b34-ol-0-0-6817]). Thus, activation of the MAPK-Erk1/2 pathway was induced increasingly by β1-AR agonists. The MAPK-Erk1/2 pathway is a cellular signal transduction pathway that can regulate cell differentiation, proliferation and cell cycle progression and is a major pathway inducing the progression of colorectal cancer ([@b9-ol-0-0-6817]--[@b13-ol-0-0-6817]). The present study revealed that lower expression of GOPC increases the risk of recurrence, metastasis, and a poor prognosis in colorectal cancer. In colorectal cancer, whether GOPC expression increases activation of MAPK-Erk1/2 via the β1-AR cascade remains unknown. In addition, although the present study suggested that the lower expression of GOPC increases the proportion of recurrence subsequent to chemotherapy, there is no report that has clarified the correlation of GOPC expression and chemoresistance. The authors are now preparing *in vitro* and *in vivo* assays focusing on the GOPC-β1-AR-MAPK-Erk1/2 pathway in colorectal cancer.

The present study demonstrated that lower GOPC expression significantly correlates with poorer OS and RFS. To the best of our knowledge, the present study is the first to clarify the correlation between GOPC expression and prognosis in colorectal cancer and demonstrates that GOPC is a possible marker for poor prognosis in this disease.
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![Results for GOPC mRNA expression by RT-qPCR. (A) Association between normal colorectal mucosa and colorectal cancer tissue by box plot chart. Statistical analyses were performed using the Wilcoxon rank-sum test. P\<0.05 was regarded as statistically significant. (B) Relative GOPC mRNA expression in 153 primary cancer tissue samples. The samples were divided into two groups split at the median value of GOPC expression. GOPC, Golgi-associated PDZ- and coiled-coil motif-containing; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.](ol-14-04-4483-g00){#f1-ol-0-0-6817}

![Kaplan-Meier curves for OS or RFS according to GOPC expression. (A) Cumulative OS for all cases. (B) Cumulative RFS for cases of curative resection. High and low groups were separated by the median score of GOPS expression. OS or RFS in the GOPC low group was significantly poorer compared with the GOPC high group. OS, overall survival; RFS, recurrence-free survival; GOPC, Golgi-associated PDZ- and coiled-coil motif-containing.](ol-14-04-4483-g01){#f2-ol-0-0-6817}

![Kaplan-Meier curves for OS according to each stage. High and low groups were separated by the median score of GOPS expression. OS in the GOPC low group was poorer compared with the GOPC high group; stage III (P=0.044) and stage IV (P=0.054). OS, overall survival; GOPC, Golgi-associated PDZ- and coiled-coil motif-containing.](ol-14-04-4483-g02){#f3-ol-0-0-6817}

![GOPC protein expression. (A) In normal colorectal mucosa, the GOPC protein was strongly expressed and localized in cytoplasm or cell membrane. Magnification, ×10. (B) GOPC protein expression in colorectal cancer tissue. Magnification, ×15. (C) GOPC protein expression in colorectal cancer tissue. Magnification, ×10. (D) GOPC protein expression in colorectal cancer tissue at the invasion front of cancer at interstitial tissue. Magnification, ×30. In colorectal cancer, expression of GOPC was observed to be relatively low at (C and D) deeper levels compared with (B) the surface area. Scale bar, 100 µm. GOPC, Golgi-associated PDZ- and coiled-coil motif-containing.](ol-14-04-4483-g03){#f4-ol-0-0-6817}

###### 

Baseline characteristics of the GOPC high and low groups.

                     GOPC expression                       
  ------------------ ------------------ ------------------ -------
  Gender                                                   
    Male             48                 47                 NS
    Female           29                 29                 
  Primary site                                             
    Colon            37                 48                 0.191
    Rectum           40                 28                 
  Tumor size, cm                                           
    Median (range)   6 (2--9.5)         4.7 (1.3--15.5)    0.552
  CEA, ng/ml                                               
    Median (range)   4 (1--204) 0.432   4.8 (0.9--7,636)   
  CA19-9, U/ml                                             
    Median (range)   13 (2--10,740)     15 (0--186,061)    0.140

GOPC, Golgi-associated PDZ- and coiled-coil motif-containing; CEA, carcinoembryonic antigen; CA, cancer antigen; NS, not significant.

###### 

Correlation between GOPC expression and pathological characteristics.

                          GOPC expression        
  ----------------------- ----------------- ---- ----------------------------------------------------
  Histological type                              
    tub1, tub2            75                69   0.097
    por, sig              2                 7    
  Lymph invasion                                 
    Negative              32                25   0.316
    Positive              45                51   
  Venous invasion                                
    Negative              50                29   0.001^[a](#tfn2-ol-0-0-6817){ref-type="table-fn"}^
    Positive              27                47   
  Tumor invasion                                 
    T0-2                  18                18   NS
    T3-4                  59                58   
  Lymph node metastasis                          
    Negative              41                39   0.871
    Positive              36                37   
  TNM stage                                      
    0-II                  40                37   0.747
    III--IV               37                39   
  Metastasis site                                
    Liver                 5                 9    
    Pleura                1                 3    
    Other                 1                 1    
  Curability                                     
    Curative              67                64   0.651
    Non-curative          10                12   

P\<0.05. GOPC, Golgi-associated PDZ- and coiled-coil motif-containing; TNM, tumor node metastasis; NS, not significant.

###### 

Results of univariate and multivariate analyses for overall survival in a Cox proportional hazards model.

                                   Univariate analysis   Multivariate analysis                                                                                 
  ----------------------- -------- --------------------- ----------------------- ------------------------------------------------------ ------- -------------- ----------------------------------------------------
  Gender                                                                                                                                                       
    Male/Female           95/58    0.821                 0.398--1.779            0.621                                                                         
  Pathological type                                                                                                                                            
    por, sig/tub1, tub2   9/144    6.240                 1.793--16.84            0.006^[a](#tfn3-ol-0-0-6817){ref-type="table-fn"}^     2.099   0.585--5.991   0.230
  Lymph invasion                                                                                                                                               
    Positive/Negative     96/57    19.18                 4.095--342.0            \<0.001^[a](#tfn3-ol-0-0-6817){ref-type="table-fn"}^   7.628   1.441--141.2   0.012^[a](#tfn3-ol-0-0-6817){ref-type="table-fn"}^
  Venous invasion                                                                                                                                              
    Positive/Negative     74/49    6.571                 2.713--19.55            \<0.001^[a](#tfn3-ol-0-0-6817){ref-type="table-fn"}^   2.345   0.896--7.406   0.084
  Tumor invasion                                                                                                                                               
    T3-4/T0-2             117/36   4.820                 1.443--29.89            0.007^[a](#tfn3-ol-0-0-6817){ref-type="table-fn"}^     2.000   0.555--12.87   0.322
  Lymph node metastasis                                                                                                                                        
    Positive/Negative     73/80    5.236                 2.264--14.20            \<0.001^[a](#tfn3-ol-0-0-6817){ref-type="table-fn"}^   2.465   0.998--7.059   0.050
  GOPC expression                                                                                                                                              
    Low/High              76/77    2.558                 1.198--5.912            0.014^[a](#tfn3-ol-0-0-6817){ref-type="table-fn"}^     1.902   0.853--4.552   0.117

P\<0.05. HR, hazard ratio; 95% CI, 95% confidence interval; T, tumor; GOPC, Golgi-associated PDZ- and coiled-coil motif-containing.

###### 

Correlation between GOPC expression and adjuvant chemotherapy or recurrence.

                          GOPC expression        
  ----------------------- ----------------- ---- ----------------------------------------------------
  Adjuvant chemotherapy                          
    Yes                   27                24   0.857
    No                    40                40   
  Recurrence                                     
    Yes                   8                 17   0.049^[a](#tfn4-ol-0-0-6817){ref-type="table-fn"}^
    No                    59                47   
  Site                                           
    Local                 2                 3    
    Lymph node            1                 4    
    Liver                 3                 3    
    Lung                  1                 5    
    Pleura                1                 2    
    Other                 0                 0    

P\<0.05. GOPC, Golgi-associated PDZ- and coiled-coil motif-containing.

###### 

Results of univariate and multivariate analyses for recurrence-free survival in a Cox proportional hazards model.

                                  Univariate analysis   Multivariate analysis                                                                                
  ----------------------- ------- --------------------- ----------------------- ---------------------------------------------------- ------- --------------- ----------------------------------------------------
  Gender                                                                                                                                                     
    Male/Female           85/46   1.072                 0.471--2.646            0.870                                                                        
  Pathological type                                                                                                                                          
    Por, sig/tub1, tub2   5/126   5.208                 1.228--15.15            0.028^[a](#tfn5-ol-0-0-6817){ref-type="table-fn"}^   2.618   0.578--8.711    0.187
  Lymph invasion                                                                                                                                             
    Positive/Negative     77/54   3.841                 1.453--13.20            0.005^[a](#tfn5-ol-0-0-6817){ref-type="table-fn"}^   2.966   0.9903--10.96   0.052
  Venous invasion                                                                                                                                            
    Positive/Negative     57/74   1.654                 0.739--3.767            0.218                                                1.672   0.639--4.365    0.290
  Tumor invasion                                                                                                                                             
    T3-4/T0-2             95/36   2.837                 0.978--12.04            0.055                                                                        
  Lymph node metastasis                                                                                                                                      
    Positive/Negative     55/76   3.555                 1.533--9.195            0.002^[a](#tfn5-ol-0-0-6817){ref-type="table-fn"}^   2.861   1.138--7.880    0.024^[a](#tfn5-ol-0-0-6817){ref-type="table-fn"}^
  GOPC expression                                                                                                                                            
    Low/High              64/67   2.706                 1.167--7.000            0.019^[a](#tfn5-ol-0-0-6817){ref-type="table-fn"}^   2.800   1.121--7.648    0.027^[a](#tfn5-ol-0-0-6817){ref-type="table-fn"}^

P\<0.05. HR, hazard ratio; 95% CI, 95% confidence interval.
